remain almost unchanged. Causes of the poor prognosis are difficulties in early discovery and resistance to all intensive chemotherapeutic agents. Extended surgical procedures, such as left upper abdominal evisceration, have a limited effect, and only at a certain stage [1] . Because of the frustration of being unable to improve survival for scirrhous gastric cancer, we conducted a phase II trial of sequential high-dose methotrexate and fluorouracil combined with doxorubicin (FAMTX) as neoadjuvant chemotherapy for potentially resectable scirrhous gastric cancer [2] . FAMTX was feasible and showed a high resectability rate, but no improvement in 2-year survival was obtained and the toxicity was moderate; therefore, we stopped the phase II trial at 20 cases.
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S-1 is a dihydropyrimidine dehydrogenase (DPD)-inhibitory fluoropyrimidine (DIF) which showed the highest response rate among many oral anticancer agents against unresectable advanced gastric cancer in early and late phase II studies [3] [4] [5] . In these phase II trials, S-1 showed a 33% response rate against scirrhous gastric cancer. Low toxicity of S-1 in the phase II trial was also one reason why we decided to start neoadjuvant chemotherapy using S-1 for scirrhous gastric cancer.
Patients and methods
Five patients were enrolled in this pilot study. All patients were diagnosed as having typical scirrhous gastric cancer by imaging diagnosis, with no incurable findings, including ascites, liver metastasis, shrinkage of the colon, and severe lymph node metastases, findings which were also confirmed by laparoscopic examination under general anesthesia. After confirmation of the resectable stage of scirrhous cancer, S-1 was administered at 50 or 60 mg/body ϫ 2 per day. One course of medication comprised 4-week administration and 2-week withdrawal.
Introduction
Scirrhous gastric cancer, also designated as linitis plastica or Borrmann type 4 tumor, is known for its aggressive behavior and poor prognosis. Even with recent developments in early detection and new anticancer drugs, treatment results for scirrhous gastric cancer After two courses of S-1 administration, patients underwent resection. The toxicity of and response to this neoadjuvant chemotherapy were evaluated according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) and the Japanese classification of gastric carcinoma [6] , respectively. The response of primary foci was evaluated by the criteria of the Japanese Research Society of Gastric Cancer for "c-lesions." Complete response (CR) was defined as the disappearance of all invasive findings, and partial response (PR) as more than a 50% decrease of the affected area on a barium-filled X-ray film taken in the same position as that before treatment. Progressive disease (PD) was defined as an increase in lesions by 25%, or the appearance of new lesions. The remaining cases were classified as stable disease (SD). Resectability rate and histological effects in the resected specimens were also evaluated.
Results
None of the five patients had any visible peritoneal dissemination, but two patients showed positive results on cytological examination of the abdominal washing from the Douglas cavity under laparoscopic examination. No toxicity of grade 3 or more was observed. The only toxicity was grade 2 pigmentation changes, in two patients.
All patients finished two courses of chemotherapy on schedule and the response rate of the neoadjuvant chemotherapy was 60% (three PR; two SD) according to the Japanese classification of gastric carcinoma [6] . Table 1 shows the laparoscopic findings, response to neoadjuvant chemotherapy, and operative and pathological findings of each patient according to the Japanese classification of gastric carcinoma. Two patients with positive results on cytological examina-tion also showed positive cytological results at laparotomy after chemotherapy. One of the two patients had localized peritoneal dissemination in the lesser omentum bursa which seemed impossible to detect at initial laparoscopy. All patients received total gastrectomy with splenectomy and D2 lymph node dissection, as well as extensive sampling of the paraaortic lymph nodes. Resection was curative in three patients according to the Japanese classification of gastric carcinoma. No serious complications developed after resection. Two patients showed mild pancreatorrhea, which prolonged their hospital stay for 2-3 weeks. Figures 1 and 2 show fluoroscopic examination results in cases 3 and 4, respectively, before and after preoperative chemotherapy. Pathological examination revealed a marked reduction in the distribution of cancer cells the patients with PR. Figure 3 shows the distribution of viable cancer cells in the resected specimen of case 4. In case 3, not only a marked shrinkage of the primary cancer in the stomach but also pathological findings suggestive of the possibility of disappearance of the cancer cells in the perigastric and paraaortic lymph nodes were noted (Fig.  4) . Even though the depth of invasion of the primary tumor was T3 in the laparoscopic examination before treatment, the final depth in the pathological report was subserosal (T2). In this patient, the final stage of disease was Ib (T2N0) whereas the pretreatment stage of disease was IVa (T3N3). Marked downstaging was achieved by preoperative chemotherapy.
The two patients with noncurative resection died of the disease, whereas the three patients with curative resection are still alive without recurrence at 24, 31, and 33 months after initiation of the neoadjuvant chemotherapy.
Discussion
Treatment results for scirrhous gastric cancer, which is called diffuse gastric cancer, linitis plastica, or Borrmann type 4 tumor in the West, remain poor because of its aggressive biological behavior, even with recent advances in the field of chemotherapy and extended surgery. At our institution, because of the frustration of being unable to improve survival, neoadjuvant chemotherapy using FAMTX was employed for patients with potentially resectable scirrhous gastric cancer in a phase II trial. The neoadjuvant chemotherapy seemed feasible, with a higher resectability rate, without any increase in the morbidity rate, compared with that of the historical controls. However, an analysis of 2-year survival when 20 patients were enrolled in the study showed no improvement over that of the historical controls. Myelosuppression was the major toxicity of the FAMTX regimen, and was observed as grade 3 or 4 neutropenia in 14 of the 20 patients (70%). Eleven of these 14 patients required granulocyte colonystimulating factor (G-CSF) support. The overall response rate was 15% (3 PRs in 20 patients). Eighteen resected specimens showed only marginal histological effects (grade 0-Ib). For these reasons we stopped the trial [2] .
There have been several reports concerning neoadjuvant chemotherapy for scirrhous gastric cancer [7] [8] [9] [10] . Suga et al. [10] described the results of neoadjuvant chemotherapy using uracil and tegafur plus cisplatin for potentially unresectable scirrhous gastric cancer patients. Ascites in 8 of 13 patients (62%) disappeared, and 10 of 28 patients became resectable [10] . However, all these studies were small in size and usually did not determine the survival benefits. The efficacy of neoadjuvant chemotherapy for scirrhous gastric cancer remains to be established because of the lack of good phase II and III studies.
As mentioned in the "Introduction", S-1 is an attractive oral anticancer agent with a high response rate and low toxicity. For scirrhous gastric cancer, S-1 showed a 33% response rate. The possibility of the outpatient use of S-1 also makes it attractive as a neoadjuvant chemotherapeutic agent. These are the reasons why we employed S-1 as an agent for neoadjuvant chemotherapy for scirrhous gastric cancer. Peritoneal dissemination is the most frequent incurable factor at laparotomy. It is the most frequent type of recurrence after curative resection and is very difficult to detect in its early stage, except by laparoscopic examination.
Because we still have no promising regimen for peritoneal dissemination and because evaluation of the effect of chemotherapy against peritoneal dissemination is difficult, patients with visible peritoneal dissemination were evaluated by laparoscopic examination and excluded from this pilot study.
As shown in the "Results," a high response rate was obtained without high-grade toxicity. The rate of curative resection was 60%, which is nearly the same as that with the FAMTX regimen. Histological effects of the neoadjuvant chemotherapy showed an unexpectedly high response by the primary lesions and the metastatic lymph nodes. We expected a change in the cytological examination results from positive to negative by the neoadjuvant chemotherapy, but two patients still showed positive results on cytological examinations after two courses of the neoadjuvant chemotherapy.
Even though the effects against peritoneal dissemination were questionable, a good impression concerning this neoadjuvant chemotherapy led us to conduct a phase II study of neoadjuvant chemotherapy using S-1 for scirrhous gastric cancer to confirm its feasibility and efficacy in a Japan Clinical Oncology Group (JCOG) trial.
